Novocure Stock Dips As Q2 Earnings Trail Estimates; Higher Costs Hit Bottom Line

  • Novocure Ltd NVCR posted a net loss of $14.6 million in Q2, compared to a net income of $1.7 million a year ago. EPS came in at $(0.14), missing the consensus of $0.01
  • Q2 net revenues were $133.5 million, representing 15% Y/Y growth, missing the estimate of $141.9 million.
  • Geography Sales: U.S ($87.1 million, +7%); Germany & other EMEA markets ($32.7 million, +29%); Japan ($8.8 million, +22%); Greater China ($4.9 million, 130%)
  • There were 3,487 active patients, representing 6% Y/Y growth and 1% sequential growth. Additionally, 1,450 prescriptions were received, +2% Y/Y and 3% sequentially.
  • R&D expenses increased 68% to $50.3 million, sales & marketing expenses were up 20% to $28.5 million, and G&A cost expanded 29% to $25.4 million.
  • The Company said that the prolonged disruption caused by COVID-19 resulted in increased volatility inpatient volumes and changes in patterns of care in certain regions that impacted the business in the second quarter.
  • Adjusted EBITDA decreased 36% to $18.1 million.
  • Price Action: NVCR shares are trading lower by 3.53% at $175.50 premarket on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceShort IdeasMoversTrading IdeasBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!